CY1116323T1 - TNFα-TREATED DISORDERS TREATMENT - Google Patents

TNFα-TREATED DISORDERS TREATMENT

Info

Publication number
CY1116323T1
CY1116323T1 CY20151100471T CY151100471T CY1116323T1 CY 1116323 T1 CY1116323 T1 CY 1116323T1 CY 20151100471 T CY20151100471 T CY 20151100471T CY 151100471 T CY151100471 T CY 151100471T CY 1116323 T1 CY1116323 T1 CY 1116323T1
Authority
CY
Cyprus
Prior art keywords
tnfα
disorders treatment
treated disorders
treated
treatment
Prior art date
Application number
CY20151100471T
Other languages
Greek (el)
Inventor
Subhashis Banerjee
Lori K Taylor
Clive E Spiegler
Daniel Edward Tracey
Eliot Keith Chartash
Rebecca S Hoffman
William T Barchuk
Philip Yan
Anwar Murtaza
Jochen G Salfeld
Steven Fischkoff
Original Assignee
Abbvie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07150442.7A external-priority patent/EP1944322B1/en
Application filed by Abbvie Biotechnology Ltd filed Critical Abbvie Biotechnology Ltd
Publication of CY1116323T1 publication Critical patent/CY1116323T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Περιγράφονται μέθοδοι θεραπευτικής αγωγής ΤΝFα-σχετιζόμενων διαταραχών που περιλαμβάνουν χορήγηση αναστολέων TNFα, συμπεριλαμβανομένων αντισωμάτων TNFα.Methods of treating TNFα-related disorders include administration of TNFα inhibitors, including TNFα antibodies.

CY20151100471T 2002-07-19 2015-05-28 TNFα-TREATED DISORDERS TREATMENT CY1116323T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39727502A 2002-07-19 2002-07-19
US41108102A 2002-09-16 2002-09-16
US41749002A 2002-10-10 2002-10-10
US45577703A 2003-03-18 2003-03-18
EP07150442.7A EP1944322B1 (en) 2002-07-19 2003-07-18 Treatment of TNF alpha related disorders

Publications (1)

Publication Number Publication Date
CY1116323T1 true CY1116323T1 (en) 2017-02-08

Family

ID=58457928

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100471T CY1116323T1 (en) 2002-07-19 2015-05-28 TNFα-TREATED DISORDERS TREATMENT

Country Status (1)

Country Link
CY (1) CY1116323T1 (en)

Similar Documents

Publication Publication Date Title
MX342777B (en) TREATMENT OF TNFα RELATED DISORDERS.
NL301145I2 (en) Tirbanibulin
NO20052760D0 (en) Process for the treatment of cancer and related methods.
NO20053042L (en) Use of spongosine (2-methoxyadenosine) for the treatment of pain, especially hyperalgesia.
NO20060030L (en) Combination therapy for b-cell disorders
NO20045043L (en) Pyrimidinone Compounds, Compositions and Methods
SE0203752D0 (en) New compounds
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
DK1206474T3 (en) Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
EA200001129A3 (en) METHOD OF OBTAINING 4-CARBOXYAMINO-2-SUBSTITUTE-1,2,3,4-TETRAHYDROCHINOLINE
DK1423384T3 (en) Pyridine derivatives such as Raf kinase inhibitors
NO20052267L (en) Compounds, Preparations and Methods
EA200400235A1 (en) COMBINED THERAPY FOR CANCER TREATMENT
NL1025873A1 (en) Dosage forms and methods of treatment with vegfr inhibitors.
TR200401316T4 (en) Compounds and methods for treating proliferative diseases
DE502004010131D1 (en) PYRIDOPYRIMIDINONE FOR THE TREATMENT OF CANCER DISORDERS
TW200508233A (en) Chk-1 inhibitors
DE60326248D1 (en) Compounds, compositions and methods for treating cellular proliferative disorders
DE60328603D1 (en) PRODRUGS OF IMIDAZOLE DERIVATIVES FOR USE AS PROTONAL PUMP INHIBITORS FOR THE TREATMENT OF e.g. PEPTIC MAGIC DISEASES
ATE359283T1 (en) SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION
NO20053071L (en) Calcilitic compounds.
DE60214019D1 (en) NITROGEN-CONTAINING HETEROCYCLES AND THEIR USE AS RAF INHIBITORS
CY1116323T1 (en) TNFα-TREATED DISORDERS TREATMENT